Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

7.300 +0.650 (+9.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Competitive Analysis In The ATTR-CM Field
Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the... 
Via Talk Markets
Topics Stocks / Equities
The Future of Healthcare: 10 Predictions For The Next Decade
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we... 
Via MarketMinute
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
This aggressive growth investor is looking at the bright side when it's raining on Wall Street. 
Via The Motley Fool
What Analysts Are Saying About Intellia Therapeutics Stock
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
How Is The Market Feeling About Intellia Therapeutics?
Via Benzinga
13 Analysts Have This To Say About Intellia Therapeutics
Via Benzinga
Cathie Wood's Ark Invest Continues To Offload UiPath, Roblox: Loads Up On GitLab, Ibotta
Ark Invest's Cathie Wood-led funds made significant trades involving GitLab, Intellia, Prime Medicine, UiPath, Ibotta, Roblox, Repare Therapeutics, and CareDx. 
Via Benzinga
Wall Street's Top 10 Stock Calls This Week - Saturday, March 1
Via Talk Markets
Topics Stocks / Equities
Intellia Therapeutics Delivers a Q4 Beat
Intellia Therapeutics reported better-than-expected results for the fourth quarter thanks to a boost in its collaboration revenue. 
Via The Motley Fool
2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street
Via The Motley Fool
Intellia Stock Dips After Morgan Stanley Downgrade, Retail Sentiment Weakens
The brokerage pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects. 
Via Stocktwits
Peering Into Intellia Therapeutics's Recent Short Interest
Via Benzinga
Peering Into Intellia Therapeutics's Recent Short Interest
Via Benzinga
9 Analysts Have This To Say About Intellia Therapeutics
Via Benzinga
This RingCentral Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Via Benzinga
Abbott To Rally Over 26%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Cathie Wood's Ark Invest Buys Into Defense And Energy Stocks Amid Trump's Inaugural Policies
Cathie Wood-led Ark Invest made significant trades involving ACCD, DE, NTLA, PATH, CCJ, OKLO, ILMN, ESLT, and ABSI. 
Via Benzinga
Topics Government
Exposures Political
Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases
An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end. 
Via Benzinga
A Glimpse of Intellia Therapeutics's Earnings Potential
Via Benzinga
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce
Ark Invest, led by Cathie Wood, made significant trades in 5 companies on Friday: RXRX, ILMN, NTLA, NET, and ADPT. 
Via Benzinga
Topics Workforce
Exposures Layoff
Why Is Intellia Therapeutics Stock Trading Lower On Friday?
Intellia Therapeutics prioritizes late-stage gene-editing programs for HAE and ATTR amyloidosis in 2025, announces leadership changes, and prepares for commercialization. 
Via Benzinga
2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025
Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space. 
Via MarketBeat
Exposures Product Safety
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?
Via The Motley Fool
From GLD To TSLA: Unlocking Today’s Best Trading Opportunities
The week kicks off amidst significant market movements shaped by geopolitical and policy developments. 
Via Talk Markets
Topics Stocks / Equities
Why Tesla Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
3 Fast-Growing Stocks Analysts See Doubling in Price
Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches. 
Via MarketBeat
Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?
There's nothing bearish at all about what it reported recently. 
Via The Motley Fool
This Beaten-Down Stock Could Soar by 354%, According to Wall Street
Maybe the Street is a bit too optimistic on this one. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS